(CercleFinance.com) – The Canadian biotechnology company Sernova announced on Wednesday the signing of a collaboration agreement with AstraZeneca in the field of cell therapy research.
Under the terms of the agreement, AstraZeneca plans to explore the potential of Sernova’s ‘Cell Pouch’ system, a device capable of creating a natural environment in the body for therapeutic cells.
Sernova’s regenerative approach is considered promising for the treatment of chronic diseases such as type 1 diabetes, hemophilia A or disease of the thyroid gland.
AstraZeneca will lead and finance the pre-clinical activities before determining the feasibility of the process.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
